As it continues to expand its presence in the non-invasive prenatal testing market, Natera has been developing its technology for the cancer diagnostics space and is poised to make announcements in that area "very soon."
NEW YORK (GenomeWeb) – A US Patent and Trademark Office board has declared that certain claims on a patent held by Sequenom are unpatentable, while it upheld other claims on the patent, US Patent No. 6,258,540.
NEW YORK (GenomeWeb) — Though the reported specificity of sequencing-based non invasive prenatal screening tests is generally more than 99 percent, this doesn't mean that false positive rates will be below one percent for all the disorders these tests now target.
NEW YORK (GenomeWeb) – Natera today announced that its cloud-based software has received CE marking, allowing the company to market the product in the European Union and other countries that accept the designation.